A
16.41
-0.20 (-1.20%)
| Previous Close | 16.61 |
| Open | 16.34 |
| Volume | 166,954 |
| Avg. Volume (3M) | 399,145 |
| Market Cap | 509,798,560 |
| Price / Book | 4.63 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 19.01% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -53.00 M |
| Levered Free Cash Flow (TTM) | -39.36 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alto Neuroscience, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.63 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 77.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2025 | 3,707,757 |
| Armistice Capital, Llc | 30 Sep 2025 | 1,636,000 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 950,000 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 667,778 |
| Alkeon Capital Management Llc | 30 Sep 2025 | 477,101 |
| Integral Health Asset Management, Llc | 30 Sep 2025 | 400,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Chardan Capital, 82.82%) | Buy |
| Median | 26.00 (58.44%) | |
| Low | 22.00 (Baird, 34.07%) | Buy |
| Average | 26.00 (58.44%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 13.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 30.00 (82.82%) | Buy | 16.53 |
| BTIG | 17 Nov 2025 | 27.00 (64.53%) | Buy | 13.80 |
| Baird | 13 Nov 2025 | 22.00 (34.06%) | Buy | 11.35 |
| Jefferies | 12 Nov 2025 | 25.00 (52.35%) | Buy | 14.20 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Jan 2026 | Announcement | Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression |
| 13 Jan 2026 | Announcement | Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology |
| 03 Dec 2025 | Announcement | Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
| 12 Nov 2025 | Announcement | Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 28 Oct 2025 | Announcement | Alto Neuroscience to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |